MyoKardia (MYOK) Announces $450M Proposed Public Offering of Common Stock
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St declines as oil prices, Treasury yields remain elevated
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- MongoDB stock drops 15% as CEO Desai resigns for Meta
- Jefferies cuts Roblox to Underperform, says rally is too optimistic
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Oppenheimer sees AI software winners as focus shifts to ROI
- Arm Holdings falls as CFO stock sale weighs on sentiment
- Cantor Fitzgerald Starts Lexicon Pharmaceuticals (LXRX) at Overweight
MyoKardia (MYOK) Prices 5.25M Share Common Offering at $105/Sh
May 13, 2020 5:48 AM EDTMyoKardia, Inc. (NASDAQ: MYOK) today announced the pricing of an underwritten public offering of 5,250,000 shares of its common stock at a public offering price of $105.00 per share, before underwriting discounts. In addition, the underwriters have a 30-day option to purchase up to an additional 787,500 shares of... More
MyoKardia (MYOK) Phase 3 EXPLORER-HCM Trial Met All Primary and All Secondary Endpoints to Treat Obstructive Hypertrophic Cardiomyopathy
May 11, 2020 7:35 AM EDTMyoKardia, Inc. (Nasdaq: MYOK) today announced positive topline data from the companys Phase 3 pivotal EXPLORER-HCM clinical trial of mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM) (clinicaltrials.gov NCT03470545). Mavacamten demonstrated a robust treatment effect: the primary and all secondary endpoints of the EXPLORER trial were met with statistical significance (p0.0006 for all... More
